Development of stable, orally bioavailable small molecule positive modulators of HGF/MET signaling for the treatment of cognitive impairment.

Positive modulators of the HGF/MET system likely represent a valuable therapeutic class with the potential to impact a variety of disorders, including neurodegenerative diseases and indications with cognitive impairment. Preclinical and clinical studies have established the therapeutic potential of fosgonimeton (ATH‐1017), a small molecule injectable positive modulator of the HGF/MET system that is currently in clinical trials in patients with Alzheimer’s disease and Parkinson’s disease. At Athira Pharma, Inc., we have worked to expand the platform of HGF/MET positive modulators by identifying small molecules with a range of properties with the potential to meet therapeutic and delivery needs of patients across neurological diseases.